viewReNeuron Group PLC

ReNeuron making good progress in clinical trial, says CFO

The third patient in stem cell specialist ReNeuron Group Plc’s (LON:RENE) early-stage clinical trial treating people with a rare eye disease will receive the therapy next week.

Researchers at Massachusetts Eye and Ear in Boston are using human retinal progenitor cells (hRPC) to possibly halt the progression of retinitis pigmentosa (RP).

Michael Hunt, chief financial officer, tells Proactive Investors “it’s important because the third patient marks the end of the first dose cohort in this particular study…so that’s good progression”.

They are carrying out a phase I/II clinical study on 15 acute sufferers of the degenerative conditions, and hunt says he expects the rest to be completed “over the course of this and possibly a little bit into next year” depending on the recruitment process.

Quick facts: ReNeuron Group PLC

Price: 140 GBX

Market: LSE
Market Cap: £44.57 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...



ReNeuron seeing increased interest across its assets from potential licensee...

ReNeuron Group PLC (LON: RENE) CFO Michael Hunt sat down with Proactive Investors at the 11th Annual Biotech Showcase in San Francisco. The UK-based developer of cell-based therapeutics in is the U.S. engaging with U.S. investors, and is looking to build out its business development...

on 01/11/2019

2 min read